Full Text View
Tabular View
No Study Results Posted
Related Studies
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
This study is currently recruiting participants.
Verified January 2013 by GlaxoSmithKline
Study NCT00338247   Information provided by GlaxoSmithKline

First Received on June 16, 2006.   Last Updated on February 28, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Neoplasms, Breast
Additional conditions recognized in this trial
Breast Neoplasms
Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
lapatinib + capecitabine
Additional drug interventions recognized in this trial
Capecitabine
Fluorouracil
Lapatinib
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services